The FDA approved pembrolizumab for certain patients with advanced endometrial cancer with DNA repair defects The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the treatment of adult patients with advanced...
Metastatic prostate cancer incidence rose after recommendation against routine screening, and FDA approves first PARP inhibitor for early-stage breast cancer for people with inherited BRCA mutations.
The FDA approved nivolumab and relatlimab-rmbw (Opdualag) for some patients with advanced melanoma The U.S. Food and Drug Administration (FDA) has approved a combination of the checkpoint inhibitors nivolumab and relatlimab-rmbw (Opdualag) for...
Pediatric patients whose cancer had relapsed were successfully matched to new gene-targeted therapies in large European trial, according to a study in the AACR journal Cancer Discovery.
The FDA approved olaparib for patients with breast cancer who have inherited BRCA mutations and have received prior neoadjuvant or adjuvant chemotherapy The U.S. Food and Drug Administration (FDA) has approved the PARP inhibitor...
FDA approves neoadjuvant immunotherapy treatment for lung cancer, and radiation might not be needed for low-risk thyroid cancer.
The FDA approved nivolumab in combination with chemotherapy for use before surgery in certain patients with non-small cell lung cancer The U.S. Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor...
Study finds lower rates of screening-related breast cancer overdiagnosis and other cancer research news of the week.
The FDA recently approved the second cellular immunotherapy to treat certain adult patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved ciltacabtagene autoleucel (Carvykti) to treat adult patients with relapsed...
Screening program reduces disparities in colorectal cancer, and seeing the challenges of getting cancer care through one woman’s story.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More